tenofovir + abacavir + efavirenz

This drug is a combination of three antiretroviral agents used in the treatment of HIV-1 infection. Tenofovir and abacavir are both nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), while efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Together, these drugs inhibit HIV-1 reverse transcriptase by different mechanisms, thereby blocking viral replication and reducing viral load. This specific triple combination (tenofovir + abacavir + efavirenz) does not correspond to any widely marketed fixed-dose product or brand name; however, each component is individually approved for use in HIV therapy and may be co-administered as separate tablets in clinical practice. The primary indication for this regimen would be the treatment of HIV-1 infection.